[go: up one dir, main page]

WO2021177317A1 - Feuille de micro-aiguille et produit pharmaceutique de type à absorption percutanée - Google Patents

Feuille de micro-aiguille et produit pharmaceutique de type à absorption percutanée Download PDF

Info

Publication number
WO2021177317A1
WO2021177317A1 PCT/JP2021/008003 JP2021008003W WO2021177317A1 WO 2021177317 A1 WO2021177317 A1 WO 2021177317A1 JP 2021008003 W JP2021008003 W JP 2021008003W WO 2021177317 A1 WO2021177317 A1 WO 2021177317A1
Authority
WO
WIPO (PCT)
Prior art keywords
microneedle sheet
needle
pincushion
dummy
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2021/008003
Other languages
English (en)
Japanese (ja)
Inventor
及川陽一
宮地邦男
義浩 橋本
日隈　薫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Think-Lands Co Ltd
Original Assignee
Think-Lands Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Think-Lands Co Ltd filed Critical Think-Lands Co Ltd
Priority to JP2021562932A priority Critical patent/JPWO2021177317A1/ja
Publication of WO2021177317A1 publication Critical patent/WO2021177317A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/42—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for desensitising skin, for protruding skin to facilitate piercing, or for locating point where body is to be pierced

Definitions

  • the present invention is suitable for application to, for example, a capsule with a needle for medical or cosmetic use using a microneedle.
  • microneedles using polymer compounds such as bioabsorbable polymers have been widely known for cosmetic purposes (see, for example, Patent Document 1).
  • This microneedle has a structure in which a drug is held in the needle itself, and is expected to be used mainly for cosmetic purposes.
  • the hollow type microneedle is attracting attention as an alternative to the injection needle.
  • a microneedle having a plurality of needle ridges has a problem that it is harder to pierce than a single injection needle.
  • the present invention has been made to solve such a problem, and an object of the present invention is to provide a drug injection tool and a microneedle sheet that can be easily pierced.
  • the microneedle sheet of the present invention is a microneedle sheet in which a plurality of fine-sized needles protruding from the surface are formed.
  • the transdermal drug of the present invention includes a microneedle sheet in which a plurality of minute-sized needles protruding from the surface are formed. It has a drug holding portion which is arranged so as to face the back surface of the microneedle sheet and forms a drug storage space for holding the drug between the microneedle sheet and the microneedle sheet.
  • the present invention can realize a drug injection tool and a microneedle sheet that can be easily stabbed.
  • FIG. It is the schematic which provides the explanation of the use (8) of the microneedle sheet in this embodiment. It is a schematic diagram which shows the structure of the microneedle sheet of Example 2. FIG. It is a schematic diagram which shows the structure of the microneedle sheet of the comparative example 2.
  • FIG. 1 shows the microneedle sheet 1 of the present invention as a whole.
  • the microneedle sheet 1 is formed with a total of 25 needle ridges 2 protruding from the sheet surface 5A of the sheet-shaped flat surface portion 5.
  • the needle ridge 2 is a micro-sized micro needle and has a conical shape as a whole.
  • the height NH from the root of the pincushion 2 (the surface position of the sheet surface 5A on which the unevenness is not formed) to the tip is about 100 to 990 ⁇ m, and the diameter ND at the root is about 100 to 500 ⁇ m.
  • the through hole 4 is formed at a position centered on or offset from the central axis of the through needle ridge 3, and the central axis of the through hole 4 is the tip 3A of the through needle ridge 3 or the vicinity of the tip 3A (the central axis is the needle ridge). It is located on the tip side of the height NH of 2).
  • the shape of the through hole 4 for example, it may be formed to have almost the same size as a whole (that is, a pillar shape such as a columnar shape or a prismatic shape), and the shape becomes larger toward the root (that is, a cone shape or a triangle shape). It may be formed in a cone shape such as a cone shape.
  • the size of the through hole 4 is not limited, but in order to secure the strength of the pincushion 2 and the amount of liquid passing through the drug, the diameter of the thinnest portion is preferably about 1/20 to 1/2 of the diameter ND of the pincushion 2. Particularly preferably, it is formed to be about 1/10 to 1/3.
  • the number of penetrating needles 3 and dummy needles 8 is not limited and can be any number, but the number of needles 2 is preferably 9 or more, more preferably 16 or more. This is because the effect of pulling the skin increases as the number of pincushions 2 increases. There is no limit to the ratio of the penetrating needles 3 and the dummy needles 8, but if there are too many dummy needles 8, the number of scratches on the skin may increase, so the ratio of the dummy needles 8 to the needles 2 is less than 70%, and even 50. It is preferably less than%.
  • the penetrating needle ridge 3 and the dummy needle ridge 8 can be arranged in any combination.
  • the penetrating needles 3 and the dummy needles 8 can be arranged alternately or randomly.
  • the heights of the penetrating needles 3 and the dummy needles 8 may be substantially the same, and one of them may be slightly higher or lower (about 5 to 30% of the height of the penetrating needles).
  • the dummy pincushion 8 plays a role of reducing the sinking of the skin surface and firmly pressing the skin, and can improve the piercing ease of the penetrating pincushion 3. can.
  • the needle ridge 2 and the through hole 4 are integrally formed by injection molding using a mold (see Special Republication WO18 / 198675), or light having a spiral phase.
  • the through hole 4 can be formed by using a laser having circularly polarized light or linearly polarized light (see Special Republication WO 17/195790).
  • the microneedle sheet 1 can be formed by pressing a sheet-shaped plastic plate in a heated state (see Japanese Patent Application Laid-Open No. 2014-141002).
  • microneedle sheet 1 there are no restrictions on the material of the microneedle sheet 1, and known inorganic and organic materials can be used as appropriate.
  • natural or artificial polymer materials bioabsorbable inorganic materials mainly composed of minerals such as calcium, and the like are used.
  • bioabsorbable polymer materials such as hyaluronic acid, polylactic acid, polyglycolic acid, and collagen, which are highly safe for the human body, are preferably used. This is because even if the pincushion 2 is broken and remains in the body, it is naturally absorbed in the body and is harmless to the human body.
  • a drug storage space for storing a drug is formed on the back surface 5B side of the sheet, and the drug is injected into the human body by piercing the needle ridge 2 into the skin of the human body, that is, the drug is injected into the human body through the penetrating needle ridge 3. It is intended to be used as the tip of a syringe that injects.
  • the shape and configuration of the drug storage space are not particularly limited, and various configurations are applied.
  • FIGS. 2 and 3 it is used for a cap 20 with a needle that is fitted to the tip of a syringe 11.
  • the syringe 11 has a general syringe structure in which a pusher 13 having a gasket at the tip is pushed into the syringe 12, and has a tip fitting portion 14 for fitting a cap with a needle on the tip side. There is.
  • the tip fitting portion 14 is provided with a screw thread for fitting the cap with a needle and a sealing rubber for sealing the drug held in the syringe.
  • the cap with a needle can be used not only with the cap 20 with a needle but also with a cap with a needle on which a general injection needle is installed.
  • the cap 20 with a needle has a microneedle in which a plurality of needle ridges 2 are formed protruding instead of an injection needle.
  • a microneedle sheet 1 is installed on the tip side of the cap 20 with a needle, and the needle ridge 2 is projected from the surface of the cap 20 with a needle by opening the periphery of the needle ridge 2.
  • a drug storage space 24 is formed inside the cap main body 21, and is connected to an intermediate needle 22 having a hollow structure.
  • the intermediate needle 22 breaks through the sealing rubber, and the drug in the syringe 12 is supplied to the drug storage space 24. Then, when the pusher 13 is pushed into the syringe 12, the drug is pushed out from the penetrating needle ridge 3 inside the needle ridge 2.
  • the microneedle sheet 1 may be used as a part of the applicator 41 attached to the tip of the injection needle.
  • the applicator 41 is attached to a commonly used anesthesia syringe body 30 for dental anesthesia.
  • the anesthesia syringe body 30 has a configuration in which a handle 31 and a slide-type syringe 33 connected to the handle are slidably stored inside the syringe case 32.
  • the syringe case 32 is loaded with a disposable cartridge 34 filled with an anesthetic.
  • a disposable cap 35 is installed at the tip of the syringe case 32.
  • a hollow needle 36 penetrating the cap 35 is inserted into the cap 35.
  • the portion of the hollow needle 36 that protrudes toward the rear side of the cap 35 is inserted into the inside of the cartridge 34. As a result, when the cap 35 is attached, the hollow needle 36 protrudes from the cap 35.
  • the applicator 41 is attached to the tip of the hollow needle 36.
  • a hollow shaft portion 42 and a tip main body portion 43 are fixed to each other.
  • the hollow needle 36 is inserted into the shaft portion 42, and the applicator 41 is attached to the hollow needle 36 by being inserted into the tip main body portion 43.
  • a microneedle sheet 1 is installed in the tip main body 43, and a needle ridge 2 projects from the tip surface 43A of the applicator 41.
  • the anesthetic agent in the cartridge 34 is pushed out, and the anesthetic agent in the cartridge 34 is pushed out from the tip of the hollow needle 36 to the back side of the microneedle sheet 1.
  • the drug is injected into the formed drug storage space 44.
  • the syringe 33 is further pushed, the drug is injected into the target portion via the penetrating needle ridge 3.
  • the microneedle sheet 1 may be used for the injector 50 as a patch-type transdermal drug.
  • the microneedle sheet 1 is installed on the fixture 55, and the cover portion 52 is fixed to the back side of the fixture 55.
  • a drug capsule 51 containing a drug is housed in the cover portion 52. That is, the fixture 55 forms a drug storage space 56 on the back side of the microneedle sheet 1, that is, the back side surface 55A of the fixture 55 and the cover portion 52.
  • the fixture 55 is formed with a through hole 57 that connects to the through hole 4 of the through needle ridge 3 in the microneedle sheet 1, and the drug storage space 56 and the through holes 57 and 4 are continuously connected.
  • the cover portion 52 is made of a flexible film-like material such as rubber. The thickness of the cover portion 52 is not limited, but is preferably about 20 to 2 mm from the relationship between strength and flexibility.
  • the drug capsule 51 contains a drug in a thin membrane material, and is formed so as to burst with a relatively small impact.
  • a protrusion 52A is formed inside the cover portion 52.
  • the drug capsule 51 bursts due to the protrusion 52A, and the drug enters the drug storage space 56. Fill up. Then, due to the pressed pressure, the drug in the drug storage space 56 is discharged through the through holes 57 and 4 and injected into the target location.
  • Substances that can be injected into the body in accordance with the present invention are intended to include pharmaceutically or biologically active substances, such as diagnostic agents, drugs, and, for example, functional foods. Other substances that provide therapeutic or health benefits include. Diagnostic substances useful in the present invention include, for example, insulin, ACTH (eg, corticotropin infusion), luteinizing hormone-releasing hormone (eg, gonadorrelin hydrochloride), growth hormone-releasing hormone (eg, cellmoreline acetate), cholesistkinin. (Sincaride), adrenocorticotropic hormone and fragments thereof (eg, teriparatide acetate), thyroid-releasing hormone and its analogs (eg, protilerin), high molecular weight substances such as secretin.
  • ACTH eg, corticotropin infusion
  • luteinizing hormone-releasing hormone eg, gonadorrelin hydrochloride
  • growth hormone-releasing hormone eg, cellmoreline acetate
  • cholesistkinin. Secar
  • ⁇ -1 anti-trypsin anti-neovascular agents, antisense, butorphanol, calcitonin and analogs
  • ceredase COX-II inhibitors
  • dermatological agents dihydroergotamine, dopamine agonists and Dopamine antagonists, enkephalin and other opioid peptides, epithelial growth factors, erythropoietin and analogs, follicular stimulating hormones, G-CSF, glucagon, GM-CSF, granisetrons, growth hormones and analogs (including growth hormone-releasing hormones), Proliferative hormone antagonists, hirudin and hirudin analogs (eg, Hirulog), IgE suppressors, insulin, insurinotropin and analogs, insulin-like proliferative factors, interferons, interleukins, luteinizing hormones, lutein
  • Prophylactic and therapeutic antigens (subunit proteins, peptides and polysaccharides, polysaccharide conjugates, toxoids, gene-based vaccines, attenuated live vaccines, reclassification, etc. related to Pyroli, salmonella, diabetes, cancer, simple herpes, human papilloma, etc.
  • Substances containing all of the major therapeutic agents including, but not limited to, resetortant vaccines, inactivating vaccines, whole cells, viral and bacterial vectors.
  • Stimulants antiallergic drugs, antiemetics, antiobesity drugs, antiosteoporetics, antiinfectious drugs, analgesics, anesthetics, appetite suppressants, antiartitis drugs, asthma treatments, antispasmodics, antispasmodics Depressants, anti-diabetic drugs, anti-histamine drugs, anti-inflammatory drugs, anti-mitiginal pain preparations, anti-sway disease preparations, antiemetics, anti-tumor drugs, anti-Parkinson's disease drugs, anti-itching drugs, antipsychotic drugs, antipyretic drugs, anti-antipsychotic drugs Cholinergic agents, benzodiazepine antagonists, vasodilators (including systemic, cardiac, peripheral and cerebral), bone stimulants, central nervous system stimulants, hormones, hypnotics, immunosuppressants, muscle relaxants, parasympathomimetics Drugs, parasympathomimetics, prostaglandins, proteins, peptides, polypeptid
  • Example 1 a microneedle sheet having 5 ⁇ 5 rows of needle threads was prepared, and through holes were formed in the central 3 ⁇ 3 rows. That is, only 9 from the center correspond to the penetrating needle ridge 3, and 16 lines forming one circumference of the outer circumference correspond to the dummy needle ridge 8. The heights of the pincushions were the same, and the height from the root was 800 ⁇ m.
  • the pitch which is the distance between the centers of the pincushions in the plane direction, was 500 ⁇ m
  • the diameter of the root of the pincushion was 150 ⁇ m
  • the diameter of the pincushion 20% from the root of the pincushion was 100 ⁇ m.
  • the microneedle sheet is formed by an injection molding method using PGA (polyglycolic acid), and then through holes are formed in nine central holes by using a laser beam.
  • Comparative Example 1 a microneedle sheet in which only 9 needle ridges were formed in a 3 ⁇ 3 row was prepared, and through holes were formed for all the microneedles.
  • the structure, material, and manufacturing method of the pincushion are the same as those in the embodiment.
  • microneedle sheets were prepared, and a needle having a microneedle sheet attached to the tip as an alternative to the needle cap of a self-injection syringe for diabetic patients having the same configuration as the syringe 11.
  • a cap was prepared and injected into rats. Insulin was used as the drug, and the insulin level of the rat was subsequently measured to determine whether or not the drug was correctly injected into the rat body.
  • Example 2 Next, Example 2 will be described.
  • Example 2 a microneedle sheet 1X having 4 ⁇ 4 rows of needle threads was prepared.
  • the pitch which is the distance between the centers of the pincushions in the plane direction, was 500 ⁇ m
  • the diameter of the root of the pincushion was 150 ⁇ m
  • the diameter of the pincushion 20% from the root of the pincushion was 100 ⁇ m.
  • the heights of the pincushions were the same, and the height from the root was 800 ⁇ m.
  • the microneedle sheet is formed by an injection molding method using PGA (polyglycolic acid), and then through holes are formed by using a laser beam.
  • PGA polyglycolic acid
  • the center distances R1 and R2 between the through needles 3 in which the through holes were formed were 1500 ⁇ m and 1000 ⁇ m, respectively.
  • the dummy needle ridge 8 is formed inside the outer penetrating needle ridge 3 sandwiched between the through needle ridges 3.
  • a microneedle sheet in which only four 2 ⁇ 2 rows of needles were formed was prepared, and through holes were formed in all the microneedles.
  • the structure, material, and manufacturing method of the pincushion are the same as those in the embodiment.
  • the center spacing R3 of the penetrating needle ridge 3 was 1410 ⁇ m.
  • Example 2 In both Example 2 and Comparative Example 2, three microneedle sheets were prepared, and a microneedle sheet was attached to the tip as an alternative to the needle cap of the self-injection syringe for diabetic patients having the same configuration as the syringe 11.
  • a cap with a needle was prepared and injected into the abdomen of rats. Rhodamine was used as the drug, and the rhodamine level of the rat was subsequently measured to determine whether or not the drug was correctly injected into the rat body.
  • Example 2 it was confirmed that rhodamine was clearly detected in the body of 3 rats and that rhodamine was injected normally.
  • Example 2 it is considered that the interval between the needles can be narrowed by forming the dummy needles 8 inside the penetrating needles 3, and the puncture property is improved by the effect of pulling the skin of the dummy needles 8.
  • the microneedle sheet (microneedle sheet 1) of the present invention is a microneedle sheet in which a plurality of fine-sized needle ridges (needle ridges 2) protruding from the surface are formed, and the needle ridges are formed.
  • the microneedle sheet can improve the ease of puncture by the action of pulling the skin of the dummy pincushion.
  • the dummy pincushion is It is characterized in that it is arranged around the pencushion.
  • the microneedle sheet can improve the ease of puncture by firmly grasping the skin with the dummy needle ridges arranged around it.
  • the dummy pincushion is characterized in that the height of the pencushion is substantially the same as that of the penetrating pincushion.
  • the microneedle sheet can make the height of the microneedle region on which the microneedle is formed uniform to improve the flatness, and suppress the inclination of the microneedle region when it comes into contact with the skin to puncture the skin. It is possible to improve the stability at the time of impact.
  • the height of the dummy pincushion is It is characterized in that it is higher than the height of the pencushion of the penetrating pincushion.
  • the height of the dummy pincushion is It is characterized in that it is lower than the height of the pincushion of the penetrating pincushion. As a result, the dummy pincushion is less likely to be stabbed into the skin, and unnecessary scratches on the skin can be suppressed.
  • the dummy pincushion is It is characterized in that it is formed inside the through needle hole.
  • the distance between the pincushions can be reduced, and the skin can be pressed and pulled by the tips of many pincushions, so that the puncture property of the pencushion can be improved.
  • the dummy pincushion is It is characterized in that it is formed both inside and outside of the through needle hole.
  • the effect of reducing the distance between the pincushions can be generated both inside and outside the pencushion, so that the puncture property of the pencushion can be further improved. That is, by increasing the total number of pincushions while limiting the number of pencushions having through holes, it is possible to extend the skin over the entire pincushion and improve the puncture property of the through pincushions.
  • the drug injection tool of the present invention has a microneedle sheet (microneedle sheet 1) in which a plurality of minute-sized needle ridges (needle ridges 2) protruding from the surface are formed, and a back surface of the microneedle sheet.
  • a drug holding portion inside of the cap main body 21, tip main body 43 that is arranged so as to face the microneedle sheet and forms a drug storage space (drug storage spaces 24, 44, 56) for holding the drug between the microneedle sheet and the microneedle sheet.
  • the pincushion A through needle ridge (through needle ridge 3) in which a through hole (through hole 4) penetrating from the surface side to the drug storage space is formed, and It is characterized by having a dummy pincushion (dummy pincushion 8) in which the through hole (through hole 4) is not formed.
  • the dummy pincushion 8 is solid and has no holes or holes, but the present invention is not limited to this.
  • all the configurations in which the drug stored in the drug storage space is not discharged from the surface side are called dummy pincushions.
  • the dummy pincushion in FIG. 8 has a through hole, the through hole 57 of the fixture 55 is formed. The effect is the same even if the configuration is not provided, and is included in the technical idea of the present invention.
  • the diameter of the dummy pincushion smaller than the penetrating pincushion, the effect of pulling the skin of the dummy pincushion is not changed, and the damage that the dummy pincushion makes to the skin due to puncture can be minimized.
  • the present invention can be applied to a medical drug injection device capable of injecting a drug into the human body or the animal body with almost no pain.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Vascular Medicine (AREA)
  • Medical Informatics (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Le problème décrit par la présente invention est de permettre une meilleure injection par des micro-aiguilles. La solution selon l'invention porte sur une feuille à micro-aiguilles 1 sur laquelle est formée une pluralité de groupes d'aiguilles 2 qui ont une petite taille et qui font saillie à partir de la surface. La feuille de micro-aiguille est caractérisée en ce que les groupes d'aiguilles 2 comprennent : un groupe d'aiguilles de pénétration 3 dans lesquelles sont formés des trous de pénétration qui pénètrent du côté de surface avant au côté de surface arrière ; et un groupe d'aiguilles factices 8 qui n'ont pas de trous de pénétration formés à l'intérieur de celles-ci. Grâce à cette configuration, le groupe d'aiguilles factices fonctionne pour saisir et tirer la surface de la peau, ce qui permet d'améliorer la facilité par laquelle une injection est réalisée.
PCT/JP2021/008003 2020-03-02 2021-03-02 Feuille de micro-aiguille et produit pharmaceutique de type à absorption percutanée Ceased WO2021177317A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021562932A JPWO2021177317A1 (fr) 2020-03-02 2021-03-02

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020035329 2020-03-02
JP2020-035329 2020-03-02

Publications (1)

Publication Number Publication Date
WO2021177317A1 true WO2021177317A1 (fr) 2021-09-10

Family

ID=77613470

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/008003 Ceased WO2021177317A1 (fr) 2020-03-02 2021-03-02 Feuille de micro-aiguille et produit pharmaceutique de type à absorption percutanée

Country Status (2)

Country Link
JP (1) JPWO2021177317A1 (fr)
WO (1) WO2021177317A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230150883A (ko) 2021-06-09 2023-10-31 카오카부시키가이샤 주사 바늘
WO2024117243A1 (fr) 2022-12-02 2024-06-06 花王株式会社 Aiguille d'injection

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003534881A (ja) * 2000-06-06 2003-11-25 ベクトン・ディキンソン・アンド・カンパニー 皮内空間への穿刺部材の穿通を強化するための方法及び装置
JP2008212588A (ja) * 2007-03-08 2008-09-18 Toppan Printing Co Ltd 針状体、針状体製造方法および薬物輸送デバイス
JP2013094224A (ja) * 2011-10-28 2013-05-20 Toppan Printing Co Ltd マイクロニードルデバイスおよびその製造方法
JP2017038781A (ja) * 2015-08-19 2017-02-23 花王株式会社 微細突起具及びその製造方法
WO2019070077A1 (fr) * 2017-10-06 2019-04-11 シンクランド株式会社 Capuchon de seringue d'injection et injecteur
US20200001065A1 (en) * 2018-06-29 2020-01-02 Johnson & Johnson Consumer Inc. Three-dimensional microfluidics devices for the delivery of actives

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003534881A (ja) * 2000-06-06 2003-11-25 ベクトン・ディキンソン・アンド・カンパニー 皮内空間への穿刺部材の穿通を強化するための方法及び装置
JP2008212588A (ja) * 2007-03-08 2008-09-18 Toppan Printing Co Ltd 針状体、針状体製造方法および薬物輸送デバイス
JP2013094224A (ja) * 2011-10-28 2013-05-20 Toppan Printing Co Ltd マイクロニードルデバイスおよびその製造方法
JP2017038781A (ja) * 2015-08-19 2017-02-23 花王株式会社 微細突起具及びその製造方法
WO2019070077A1 (fr) * 2017-10-06 2019-04-11 シンクランド株式会社 Capuchon de seringue d'injection et injecteur
US20200001065A1 (en) * 2018-06-29 2020-01-02 Johnson & Johnson Consumer Inc. Three-dimensional microfluidics devices for the delivery of actives

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230150883A (ko) 2021-06-09 2023-10-31 카오카부시키가이샤 주사 바늘
DE112022002029T5 (de) 2021-06-09 2024-01-18 Kao Corporation Injektionsnadel
WO2024117243A1 (fr) 2022-12-02 2024-06-06 花王株式会社 Aiguille d'injection
JP2024080677A (ja) * 2022-12-02 2024-06-13 花王株式会社 注射針
JP2024081783A (ja) * 2022-12-02 2024-06-18 花王株式会社 注射針
JP7503699B2 (ja) 2022-12-02 2024-06-20 花王株式会社 注射針
JP7602680B2 (ja) 2022-12-02 2024-12-18 花王株式会社 注射針
EP4628142A1 (fr) 2022-12-02 2025-10-08 Kao Corporation Aiguille d'injection

Also Published As

Publication number Publication date
JPWO2021177317A1 (fr) 2021-09-10

Similar Documents

Publication Publication Date Title
JP4427325B2 (ja) 薬品送出技術
CN111212675B (zh) 用于将微针阵列施用于皮肤的施用装置
US10695547B2 (en) Microneedle injection apparatus comprising an inverted actuator
KR101830398B1 (ko) 무고통 및 무패치의 슈팅 마이크로구조체
KR101747099B1 (ko) 생체적합성 고분자를 이용한 마이크로니들의 제조방법
JP6865524B2 (ja) 治療剤を送達するためのマイクロアレイおよび使用方法
EP2906284B1 (fr) Applicateur régulé par une force pour appliquer un dispositif à micro-aiguille sur la peau
US9180283B2 (en) System for transporting fluid across or into a biological barrier, device and capsule as part of the system
JP6709562B2 (ja) 薬剤でコーティングされたマイクロニードルアレイの製造方法
US20040138610A1 (en) Active agent delivery device having composite members
JP2016511014A5 (fr)
JP2019170690A (ja) マイクロニードル連続注入装置
WO2021177317A1 (fr) Feuille de micro-aiguille et produit pharmaceutique de type à absorption percutanée
KR20220024157A (ko) 바늘 밀도가 불균일한 마이크로니들 어레이
US20250128035A1 (en) Microneedle array coated with drug
KR102198814B1 (ko) 마이크로 니들
RU2814278C2 (ru) Микроигольная система для введения вакцины от гепатита
CN114534086A (zh) 一种重组亚单位微针疫苗及其制备方法和应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21764607

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021562932

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 01/12/2022)

122 Ep: pct application non-entry in european phase

Ref document number: 21764607

Country of ref document: EP

Kind code of ref document: A1